RxDoctor Payments Data

Kimberly Miller

Nurse Practitioner · Jackson, MSNPI 1073548350

Payments from drug & device makers

$2,370in general payments, 2019–2025

Across 103 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$794
  • Merck$437
  • Boehringer Ingelheim$379
  • Pfizer$123
  • Inspire Medical Systems, Inc.$122
  • Scpharmaceuticals Inc.$110
  • plus $404 from 6 others

What the payments were for

  • Food & beverage$2,360100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,370 in reported general payments places this provider in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$35,936
Medicare patients
278
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan253$266,794
FarxigaDapagliflozin Propanediol149$128,716
JardianceEmpagliflozin109$123,039
EliquisApixaban45$55,701
VerquvoVericiguat33$29,845
XareltoRivaroxaban17$17,994
CorlanorIvabradine Hcl12$10,202
DapagliflozinDapagliflozin Propanediol16$7,444
Metoprolol Succinate166$3,142
PaxlovidNirmatrelvir/Ritonavir22$2,858
Isosorbide Dinitrate33$1,977
Hydralazine Hcl98$1,841
Potassium Chloride51$1,839
Atorvastatin Calcium143$1,272
Spironolactone142$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$96$266,794253 claims
AstraZenecaFarxiga$794$128,716149 claims
Boehringer IngelheimJardiance$379$123,039109 claims
PfizerEliquis, Paxlovid$123$58,55967 claims
MerckVerquvo$437$29,84533 claims
Johnson & JohnsonXarelto$31$17,99417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →